HOME Top Market Reports High Throughput Process Development Market by Product & Service (Instrument, Software and Service), Molecule Type (Monoclonal Antibodies, Recombinant Insulin), Process (Upstream, Downstream), End User (Contract Manufacturing Organization) - Forecast to 2021

High Throughput Process Development Market by Product & Service (Instrument, Software and Service), Molecule Type (Monoclonal Antibodies, Recombinant Insulin), Process (Upstream, Downstream), End User (Contract Manufacturing Organization) - Forecast to 2021

By: marketsandmarkets.com
Publishing Date: April 2017
Report Code: BT 5157

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The global high throughput process development market is expected to reach USD 19.78 Billion in 2021 from USD 9.91 Billion in 2016, at a CAGR of 14.8% from 2016 to 2021.

The global market is segmented on the basis of product and service, end user, molecule type, process, and region. On the basis of product and service, the market is broadly segmented into consumables and reagents, instruments, and software & services. In 2016, the consumables and reagents segment accounted for the largest share of the market. The advent of novel technologies, enhancements in existing technologies for high throughput process development, and the growing use of automated instruments (resulting in the efficient and optimal utilization of reagents) are the key drivers for the consumables and reagents segment.

On the basis of end user, the market is segmented into biopharmaceutical manufacturers and contract manufacturing organizations. In 2016, the biopharmaceutical manufacturers segment accounted for the largest share of the market. The contract manufacturing organizations segment, on the other hand, is expected to be the fastest-growing end-user segment of the market during the forecast period. High R&D investments by biotechnology companies to accelerate drug manufacturing and increasing pressure from regulatory authorities to lower the cost of production are the major factors driving the growth of the biopharmaceutical manufacturers’ end-user segment.

Growth in the market is mainly driven by the increasing R&D spending, technological advancements in process development, growth in the biopharmaceutical industry, and growing pressure to lower the cost of manufacturing. However, factors such as the high cost of technology and equipment in this market and lack of adequate infrastructural facilities are restraining the growth of this market to a certain extent.

The high throughput process development market is dominated by established players such as Danaher Corporation (U.S.), GE Healthcare (U.S.), Agilent Technologies (U.S.), Merck Millipore (Germany), and Thermo Fisher Scientific (U.S.).

Target Audience

  • High throughput process development manufacturers, suppliers, and providers.
  • Biopharmaceutical firms
  • Contract manufacturing organizations

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

  • The market study doesn’t cover the market size in terms of volume
  • Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
  • Company developments not reported in the public domain are not included in this report

Particular

Scope

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • RoE
  • Asia-Pacific
  • Rest of the World (RoW)

Historical Years

2014

Base Year

2015

Estimated Year

2016-e

Forecast Period

2016-e–2021-p

Revenue Currency

USD

Market Segmentation

Global High Throughput Process Development Market, by Product and Service

  • Consumables and Reagents
  • Instruments
  • Software and Services

Global High Throughput Process Development Market, by End User

  • Biopharmaceutical Manufacturers
  • Contract Manufacturing Organizations

Global High Throughput Process Development Market, by Process

  • Upstream
  • Downstream

Global High Throughput Process Development Market, by Molecule Type

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Insulin
  • Human Growth Hormone
  • Other Molecules (Interferon and Interleukin)

Global High Throughput Process Development Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • RoE
  • Asia-Pacific
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Research Approach
           2.1.1 Key Data From Secondary Sources
           2.1.2 Key Data From Primary Sources
                    2.1.2.1 Key Industry Insights
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Assumptions for the Study

3 Executive Summary (Page No. - 24)

4 Premium Insights (Page No. - 29)
    4.1 High Throughput Process Development Market Snapshot: 2016 vs 2021
    4.2 High Throughput Process Development Market, By Product and Region
    4.3 High Throughput Process Development Market, By Molecule Type, 2016 vs 2021 (USD Billion)
    4.4 High Throughput Process Development Market, By Process, 2016 vs 2021 (USD Billion)
    4.5 High Throughput Process Development Market, By End User, 2016 vs 2021 (USD Billion)
    4.6 High Throughput Process Development Market, By Region

5 Market Overview (Page No. - 33)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing R&D Spending
                    5.2.1.2 Technological Advancements in Process Development
                    5.2.1.3 Growth in the Biopharmaceutical Industry
                    5.2.1.4 Growing Pressure to Lower the Cost of Manufacturing
           5.2.2 Restraints
                    5.2.2.1 High Cost of Advanced High Throughput Process Development Technologies and Lack of Adequate Infrastructural Facilities
           5.2.3 Current Trends
                    5.2.3.1 Outsourcing to Contract Manufacturing Organizations
                    5.2.3.2 Adoption of Quality By Design(QBD) Principles

6 High Throughput Process Development Market, By Product & Service (Page No. - 40)
    6.1 Introduction
    6.2 Consumables & Reagents
    6.3 Instruments
    6.4 Software & Services

7 High Throughput Process Development Market, By End User (Page No. - 47)
    7.1 Introduction
    7.2 Biopharmaceutical Manufacturers
    7.3 Contract Manufacturing Organizations

8 High Throughput Process Development Market, By Molecule Type (Page No. - 53)
    8.1 Introduction
    8.2 Monoclonal Antibodies
    8.3 Vaccines
    8.4 Recombinant Insulin
    8.5 Human Growth Hormones
    8.6 Other Molecules

9 High Throughput Process Development Market, By Process (Page No. - 64)
    9.1 Introduction
    9.2 Downstream Processing
    9.3 Upstream Processing

10 High Throughput Process Development Market, By Region (Page No. - 71)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 U.K.
             10.3.3 Rest of Europe (RoE)
     10.4 Asia-Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 97)
     11.1 Overview
     11.2 Comparative Assessment of Key Market Players
     11.3 Compettitive Situation and Trends
             11.3.1 Product Launches
             11.3.2 Agreements and Partnerships
             11.3.3 Acquisitions
             11.3.4 Expansions
             11.3.5 Other Strategies

12 Company Profiles (Page No. - 105)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Introduction
     12.2 Danaher Corporation
     12.3 GE Healthcare
     12.4 Thermo Fisher Scientific Inc.
     12.5 Merck Millipore
     12.6 Agilent Technologies, Inc.
     12.7 Bio-Rad Laboratories, Inc.
     12.8 Eppendorf AG
     12.9 Perkinelmer, Inc.
     12.10 Sartorius Stedim Biotech
     12.11 Tecan Group Ltd.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 136)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Other Developments
     13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.5 Introducing RT: Real-Time Market Intelligence
     13.6 Available Customizations
     13.7 Related Reports
     13.8 Author Details


List of Tables (85 Tables)

Table 1 High Throughput Process Development Market Size, By Product & Service, 2014–2021 (USD Million)
Table 2 High Throughput Process Development Consumables and Reagents Market Size, By Region, 2014–2021 (USD Million)
Table 3 North America: High Throughput Process Development Consumables and Reagents Market Size, By Country, 2014–2021 (USD Million)
Table 4 Europe: High Throughput Process Development Consumables and Reagents Market Size, By Country, 2014–2021 (USD Million)
Table 5 High Throughput Process Development Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 6 North America: High Throughput Process Development Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 7 Europe: High Throughput Process Development Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 8 High Throughput Process Development Software and Services Market Size, By Region, 2014–2021 (USD Million)
Table 9 North America: High Throughput Process Development Software and Services Market Size, By Country, 2014–2021 (USD Million)
Table 10 Europe: High Throughput Process Development Software and Services Market Size, By Country, 2014–2021 (USD Million)
Table 11 Global Market Size, By End User, 2014-2021 (USD Million)
Table 12 Market Size for Biopharmaceutical Manufacturers, By Region, 2014-2021 (USD Million)
Table 13 North America: Market Size for Biopharmaceutical Manufacturers, By Country, 2014–2021 (USD Million)
Table 14 Europe: Market Size for Biopharmaceutical Manufacturers, By Country, 2014–2021 (USD Million)
Table 15 Market Size for Contract Manufacturing Organizations, By Region, 2014-2021 (USD Million)
Table 16 North America: Market Size for Contract Manufacturing Organizations, By Country, 2014–2021 (USD Million)
Table 17 Europe: Market Size for Contract Manufacturing Organizations, By Country, 2014–2021 (USD Million)
Table 18 Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 19 Therapeutic Monoclonal Antibodies Approved By Fda in 2016
Table 20 Market Size for Monoclonal Antibodies, By Region, 2014–2021 (USD Million)
Table 21 North America: Market Size for Monoclonal Antibodies, By Country, 2014–2021 (USD Million)
Table 22 Europe: Market Size for Monoclonal Antibodies, By Country, 2014–2021 (USD Million)
Table 23 Market Size for Vaccines, By Region, 2014–2021 (USD Million)
Table 24 North America: Market Size for Vaccines, By Country, 2014–2021 (USD Million)
Table 25 Europe: Market Size for Vaccines, By Country, 2014–2021 (USD Million)
Table 26 Market Size for Recombinant Insulin, By Region, 2014–2021 (USD Million)
Table 27 North America: Market Size for Recombinant Insulin, By Country, 2014–2021 (USD Million)
Table 28 Europe: Market Size for Recombinant Insulin, By Country, 2014–2021 (USD Million)
Table 29 Market Size for Human Growth Hormones, By Region, 2014–2021 (USD Million)
Table 30 North America: Market Size for Human Growth Hormones, By Country, 2014–2021 (USD Million)
Table 31 Europe: Market Size for Human Growth Hormones, By Country, 2014–2021 (USD Million)
Table 32 Market Size for Other Molecules, By Region, 2014-2021 (USD Million)
Table 33 North America: Market Size for Other Molecules, By Country, 2014–2021 (USD Million)
Table 34 Europe: Market Size for Other Molecules, By Country, 2014–2021 (USD Million)
Table 35 Market Size, By Process, 2014–2021 (USD Million)
Table 36 Market Size for Downstream Processing, By Region, 2014–2021 (USD Million)
Table 37 North America: Market Size for Downstream Processing, By Country, 2014–2021 (USD Million)
Table 38 Europe: Market Size for Downstream Processing, By Country, 2014–2021 (USD Million)
Table 39 Market Size for Upstream Processing, By Region, 2014–2021 (USD Million)
Table 40 North America: Market Size for Upstream Processing, By Country, 2014–2021 (USD Million)
Table 41 Europe: Market Size for Upstream Processing, By Country, 2014–2021 (USD Million)
Table 42 Market Size, By Region, 2014–2021 (USD Million)
Table 43 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 44 North America: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 45 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 46 North America: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 47 North America: Market Size, By Process, 2014–2021 (USD Million)
Table 48 U.S.: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 49 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 50 U.S.: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 51 U.S.: Market Size, By Process, 2014–2021 (USD Million)
Table 52 Canada: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 53 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 54 Canada: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 55 Canada: Market Size, By Process, 2014–2021 (USD Million)
Table 56 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 57 Europe: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 58 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 59 Europe: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 60 Europe: Market Size, By Process, 2014–2021 (USD Million)
Table 61 Germany: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 62 Germany: Market Size, By End User, 2014–2021 (USD Million)
Table 63 Germany: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 64 Germany: Market Size, By Process, 2014–2021 (USD Million)
Table 65 U.K.: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 66 U.K.: Market Size, By End User, 2014–2021 (USD Million)
Table 67 U.K.: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 68 U.K.: Market Size, By Process, 2014–2021 (USD Million)
Table 69 RoE: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 70 RoE: Market Size, By End User, 2014–2021 (USD Million)
Table 71 RoE: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 72 RoE: Market Size, By Process, 2014–2021 (USD Million)
Table 73 Asia-Pacific: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 74 Asia-Pacific: Market Size, By End User, 2014–2021 (USD Million)
Table 75 Asia-Pacific: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 76 Asia-Pacific: Market Size, By Process, 2014–2021 (USD Million)
Table 77 RoW: Market Size, By Product & Service, 2014–2021 (USD Million)
Table 78 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 79 RoW: Market Size, By Molecule Type, 2014–2021 (USD Million)
Table 80 RoW: Market Size, By Process, 2014–2021 (USD Million)
Table 81 Product Launches, 2014–2016
Table 82 Agreements and Partnerships, 2014–2016
Table 83 Acquisitions, 2014–2016
Table 84 Expansions, 2014–2016
Table 85 Other Strategies, 2014–2016


List of Figures (38 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market: Top-Down Approach
Figure 4 Market: Bottom-Up Approach
Figure 5 Market Data Triangulation Methodology
Figure 6 Global Market, By Molecule Type, 2016 vs 2021
Figure 7 Global Market, By End User, 2016 vs 2021
Figure 8 Global Market, By Process, 2016 vs 2021
Figure 9 Global Market, By Product and Service, 2016 vs 2021
Figure 10 Geographical Snapshot of the Market
Figure 11 Increasing Demand for Biopharmaceuticals is an Important Growth Driver
Figure 12 Consumables and Reagents Accounted for the Largest Market Share in 2016
Figure 13 Monoclonal Antibodies Segment Dominated the Market, By Molecule Type, in 2016
Figure 14 Downstream Processing Segment Dominated the Market in 2016
Figure 15 Biopharmaceutical Manufacturers Dominated the End-User Market in 2016
Figure 16 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 17 High-Throughput Process Development Market: Drivers and Restraints
Figure 18 Pharmaceutical R&D Expenditure, By Region/Country, 2000 vs 2010 vs 2014
Figure 19 Consumables and Reagents Segment to Dominate the Market During the Forecast Period
Figure 20 Biopharmaceutical Manufacturers to Form the Largest End-User Segment in the Market
Figure 21 Monoclonal Antibodies Commanded the Largest Share of the Global Market in 2016
Figure 22 Downstream Processing Commanded the Largest Share of the Global Market in 2016
Figure 23 Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 24 North America: Market Snapshot
Figure 25 Asia-Pacific: Market Snapshot
Figure 26 Companies Majorly Pursued the Strategy of Product Launches to Enhance Their Market Presence
Figure 27 Battle for Market Share: Product Launches—Key Growth Strategy Adopted By Market Players
Figure 28 Geographic Revenue Mix of the Prominent Players in the High Throughput Process Development Market
Figure 29 Danaher Corporation: Company Snapshot (2015)
Figure 30 GE Healthcare: Company Snapshot (2015)
Figure 31 Thermo Fisher Scientific Inc.: Company Snapshot (2015)
Figure 32 Merck Millipore: Company Snapshot (2015)
Figure 33 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 34 Bio-Rad Laboratories, Inc.: Company Snapshot (2015)
Figure 35 Eppendorf AG: Company Snapshot (2015)
Figure 36 Perkinelmer, Inc.: Company Snapshot (2015)
Figure 37 Sartorius Stedim Biotech: Company Snapshot (2015)
Figure 38 Tecan Group Ltd.: Company Snapshot (2015)

The global high throughput process development market is expected to reach USD 19.78 Billion in 2021 from USD 9.91 Billion in 2016, at a CAGR of 14.8% from 2016 to 2021.
Growth in the market is mainly driven by the increasing R&D spending, technological advancements in process development, growth in the biopharmaceutical industry, and growing pressure to lower the cost of manufacturing. However, factors such as the high cost of technology and equipment in this market and lack of adequate infrastructural facilities are restraining the growth of this market to a certain extent.

The market is segmented on the basis of molecule type, end user, process, product and service, and region. Based on molecule type, the market is segmented into monoclonal antibodies, vaccine, recombinant insulin, human growth hormones, and others (interferons and interleukins). The monoclonal antibodies segment accounted for the largest share of the global market in 2016. The large share of this segment is attributed to the increasing adoption of targeted immunotherapy and the increasing number of U.S. FDA-cleared therapeutic monoclonal antibodies.

Based on process, the market is segmented into upstream and downstream. The downstream processing segment accounted for the largest share of the global high throughput process development market in 2016. This is attributed to the increasing demand for purified biosimilars and the increased adoption of disposable technologies in the manufacturing process of biosimilars. However, high labor costs and high costs associated with purification materials in downstream processing are likely to restrain the growth of this market during the forecast period.

High Throughput Process Development Market

Geographically, North America (comprising the U.S. and Canada) accounted for the largest share of the global high throughput process development market in 2016. Factors such as increase in R&D spending by pharmaceutical and biopharmaceutical companies, growing demand for technical tools for improving the production quality of biological materials, collective pressure towards lowering the cost of manufacturing biological materials, rising demand for reducing product development timelines, and the presence of major players in this region are driving the growth of the North American market. Compared to the mature markets, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as increasing R&D spending, growing trend of outsourcing, growing public-private partnerships, and increasing government funding for infrastructural development are driving the growth of the Asia-Pacific market.

Major players operating in the high throughput process development market include Danaher Corporation (U.S.), GE Healthcare (U.S.), Agilent Technologies (U.S.), Merck Millipore (Germany), and Thermo Fisher Scientific (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo